Pharmaceuticals In India
- All
- News
- Videos
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Stock Market Highlights: Markets End In Green As Wall Street, Asian Peers Edge Higher
Sensex Today | Nifty 50 | Stock Market Highlights: GIFT Nifty indicated another positive start for Nifty50 and the Sensex.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
'National Image Dented': Top Court Slams Pharma Firm Over Cough Syrup Deaths In Uzbekistan
"Do you realise what dent it has caused to the country's image?" the Supreme Court on Thursday asked a pharmaceutical firm whose cough syrups allegedly resulted in the death of more than 18 children in Uzbekistan.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Stock Market Highlights: Markets End In Green As Wall Street, Asian Peers Edge Higher
Sensex Today | Nifty 50 | Stock Market Highlights: GIFT Nifty indicated another positive start for Nifty50 and the Sensex.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
'National Image Dented': Top Court Slams Pharma Firm Over Cough Syrup Deaths In Uzbekistan
"Do you realise what dent it has caused to the country's image?" the Supreme Court on Thursday asked a pharmaceutical firm whose cough syrups allegedly resulted in the death of more than 18 children in Uzbekistan.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
